Literature DB >> 33717971

Present and future scope of recombinant parathyroid hormone therapy in orthopaedics.

Arnab Sain1, Hemant Bansal1, Kirubakaran Pattabiraman1, Vijay Sharma1.   

Abstract

Parathyroid Hormone (PTH) has a significant role in calcium metabolism. Its intermittent administration has an anabolic effect on bone mineralization. Teriparatide (PTH 1-34), a recombinant form of parathyroid hormone, is useful in the treatment of osteoporosis, fracture healing, non-union, stress fracture, augmentation of implant fixation with bone, and chondroprotection in osteoarthritis. The present review article will elaborate on the potential approved uses of recombinant PTH in orthopedics and its evolving role in the management of fracture osteosynthesis and other common challenging bone pathologies.
© 2021 Delhi Orthopedic Association. All rights reserved.

Entities:  

Keywords:  Fracture healing; Osteonecrosis; Osteoporosis; Parathyroid hormone (PTH); Stress fracture; Teriparatide

Year:  2021        PMID： 33717971      PMCID： PMC7920101          DOI： 10.1016/j.jcot.2021.01.019

Source DB:  PubMed          Journal:  J Clin Orthop Trauma        ISSN： 0976-5662


  44 in total

1.  Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis.

Authors:  Erik R Sampson; Matthew J Hilton; Ye Tian; Di Chen; Edward M Schwarz; Robert A Mooney; Susan V Bukata; Regis J O'Keefe; Hani Awad; J Edward Puzas; Randy N Rosier; Michael J Zuscik
Journal:  Sci Transl Med       Date:  2011-09-21       Impact factor: 17.956

Review 2.  Parathyroid hormone--a drug for orthopedic surgery?

Authors:  Ralf Skripitz; Per Aspenberg
Journal:  Acta Orthop Scand       Date:  2004-12

3.  Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.

Authors:  R Lindsay; J Nieves; C Formica; E Henneman; L Woelfert; V Shen; D Dempster; F Cosman
Journal:  Lancet       Date:  1997-08-23       Impact factor: 79.321

4.  Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.

Authors:  F Cosman; J Nieves; L Woelfert; C Formica; S Gordon; V Shen; R Lindsay
Journal:  J Bone Miner Res       Date:  2001-05       Impact factor: 6.741

5.  Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures.

Authors:  Per Aspenberg; Harry K Genant; Torsten Johansson; Antonio J Nino; Kyoungah See; Kelly Krohn; Pedro A García-Hernández; Christopher P Recknor; Thomas A Einhorn; Gail P Dalsky; Bruce H Mitlak; Anke Fierlinger; Mark C Lakshmanan
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

Review 6.  The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis.

Authors:  U S Masiukiewicz; K L Insogna
Journal:  Aging (Milano)       Date:  1998-06

7.  Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial.

Authors:  Mohit Bhandari; Ling Jin; Kyoungah See; Russel Burge; Nigel Gilchrist; Richard Witvrouw; Kelly D Krohn; Margaret R Warner; Qasim I Ahmad; Bruce Mitlak
Journal:  Clin Orthop Relat Res       Date:  2016-03-01       Impact factor: 4.176

Review 8.  Teriparatide for treating delayed union and nonunion: A systematic review.

Authors:  Anissa Feby Canintika; Ismail Hadisoebroto Dilogo
Journal:  J Clin Orthop Trauma       Date:  2019-11-05

9.  Parathyroid hormone treatment increases fixation of orthopedic implants with gap healing: a biomechanical and histomorphometric canine study of porous coated titanium alloy implants in cancellous bone.

Authors:  Henrik Daugaard; Brian Elmengaard; Troels Andreassen; Joan Bechtold; Anders Lamberg; Kjeld Soballe
Journal:  Calcif Tissue Int       Date:  2011-01-21       Impact factor: 4.333

10.  Can Three Months of Teriparatide Be One of Treatment Options for Osteoporotic Vertebral Compression Fracture Patients?

Authors:  Jung Hoon Kang; Sang Mi Yang; Soo Bin Im; Je Hoon Jeong
Journal:  Korean J Neurotrauma       Date:  2019-04-25
View more
  1 in total

Review 1.  Timing of osteoporosis therapies following fracture: the current status.

Authors:  Rajan Palui; Harsh Durgia; Jayaprakash Sahoo; Dukhabandhu Naik; Sadishkumar Kamalanathan
Journal:  Ther Adv Endocrinol Metab       Date:  2022-07-22       Impact factor: 4.435
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.